Trans-Hit Biomarkers signs a Preferred Provider Agreement with Covance.

Montreal, October 7th, 2010 - Trans-Hit Biomarkers Inc. announced today that it has entered into an agreement with Covance Inc. to enhance Trans-Hit Biomarkers’s ability to provide services to research institutions, diagnostic, and biopharmaceutical companies for the development of biomarkers.

Under the terms of the agreement,Trans-Hit Biomarkers will work with Covance to provide services for executing international studies aimed at collecting prospective clinical samples needed for clinical validation of new biomarkers.

“When international multicenter prospective studies are needed for the clinical validation of new biomarkers, maintaining high-quality standards for sampling, shipping and storing biospecimen is critical” said Pascal Puchois, Chief Executive Officer. "By leveraging Covance's strong central laboratory leadership, worldwide presence and high-quality standards, our customers and partners will have a unique access to more sources of expertise to bring their new diagnostic products to market."

About Covance

Covance (NYSE: CVD), with annual revenues greater than $1.8 billion is the most experienced provider of clinical trial laboratory services in the world.  In the past five years alone, Covance laboratories have conducted over 186 million laboratory tests for more than 3,400 clinical trial protocols in over 90 countries working with more than 110,000 investigator sites. Covance's central laboratory network includes dedicated facilities in Indianapolis, Geneva, Singapore and Shangai. Information on Covance can be obtained through its website at .

 About Trans-Hit Biomarkers

Trans-Hit Biomarkers is a privately held company whose mission is to advance innovative biomarkers into more valuable and competitive products. Trans-Hit Biomarkers is collaborative research organization forging strong partnerships between human biobanks, CROs, diagnostic companies and technology transfer offices. Servies includes access to biospecimen collection, regulatory services, new biomarkers in-licensing opportunities from TTOs,… To learn more about Trans-Hit Biomarkers, visit at